In patients with cancer of unknown primary, do you routinely send molecular testing to help determine primary tumor origin?

The NCCN designates tumor sequencing and use of gene signature profiling as a category 3 recommendation. This is more or less consistent with NIH and ESMO guidelines in that that the impact on patient outcome remains questionable and unproven.

There are multiple commercial assays in this space. The p...